ALX Oncology Holdings Inc. Files 8-K on Shareholder Vote Matters

Ticker: ALXO · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1810182

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: ALXO

TL;DR

ALXO filed an 8-K about a shareholder vote on 6/11. Details TBD.

AI Summary

ALX Oncology Holdings Inc. filed an 8-K on June 12, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2025. The filing does not contain specific details about the vote's outcome or the matters discussed.

Why It Matters

This filing indicates that ALX Oncology is engaging with its shareholders on important corporate decisions. Investors should monitor the outcome of these votes for potential impacts on the company's strategic direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new material financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted for a vote of security holders on June 11, 2025?

The filing states that matters were submitted to a vote of security holders, but it does not specify what those matters were.

When was this 8-K report filed?

The 8-K report was filed on June 12, 2025.

What is the principal business of ALX Oncology Holdings Inc.?

ALX Oncology Holdings Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

Where are ALX Oncology Holdings Inc.'s principal executive offices located?

The principal executive offices are located at 323 Allerton Avenue, South San Francisco, California 94080.

What is the Commission File Number for ALX Oncology Holdings Inc.?

The Commission File Number for ALX Oncology Holdings Inc. is 001-39386.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding ALX ONCOLOGY HOLDINGS INC (ALXO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing